文献速递心力衰竭与心肌病

恩格列净对射血分数降低心力衰竭患者临床稳定性的影响:EMPEROR-Reduced 试验

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
PubMed 文献 · Circulation · 2020-10-21

EMPEROR-Reduced 试验随机分配 3730 例射血分数≤40% 的心衰患者,在推荐治疗基础上接受恩格列净 10 mg 每日一次或安慰剂,中位随访 16 个月。恩格列净降低了死亡、心衰住院或需静脉治疗的紧急心衰就诊的复合风险(HR 0.76;95%CI 0.67-0.87;P<0.0001),并减少了住院和门诊加重的总心衰事件。

要点

  • 恩格列净降低复合终点风险(HR 0.76,95%CI 0.67-0.87,P<0.0001),12 天即达统计学显著。
  • 恩格列净减少需重症监护(HR 0.67)或需血管活性药物/机械干预(HR 0.64)的心衰住院总数。
  • 恩格列净减少利尿剂强化(HR 0.67)并改善 NYHA 心功能分级,28 天可见且长期维持。

核心结论

  • 在射血分数降低的心衰患者中,恩格列净降低了住院和门诊加重心衰事件的风险及总数,获益在治疗开始后早期出现并持续整个双盲治疗期。

研究设计与样本

  • 多中心随机双盲安慰剂对照试验,纳入 3730 例 NYHA II-IV 级、射血分数≤40% 的心衰患者,随机接受恩格列净 10 mg 每日一次或安慰剂,中位随访 16 个月。

主要发现

  • 恩格列净组 415 例 vs 安慰剂组 519 例发生死亡、心衰住院或需静脉治疗的紧急/急诊心衰就诊,HR 0.76(95%CI 0.67-0.87),P<0.0001,随机化后 12 天即达统计学显著。
  • 恩格列净减少需重症监护的心衰住院总数(HR 0.67;95%CI 0.50-0.90;P=0.008)和需血管升压药或正性肌力药或机械/手术干预的心衰住院总数(HR 0.64;95%CI 0.47-0.87;P=0.005)。
  • 恩格列净组报告利尿剂强化者更少(297 vs 414;HR 0.67;95%CI 0.56-0.78;P<0.0001)。
  • 恩格列净组 NYHA 心功能分级改善的可能性高 20%-40%,恶化的可能性低 20%-40%,随机化后 28 天显著并长期维持。
  • 安慰剂组任何住院或门诊加重心衰事件风险高(48.1/100 患者年随访),恩格列净降低该风险(HR 0.70;95%CI 0.63-0.78;P<0.0001)。

临床怎么用

  • 对射血分数降低的心衰患者,可考虑在推荐治疗基础上加用恩格列净 10 mg 每日一次,以减少住院和门诊加重心衰事件。
  • 恩格列净的临床稳定性获益在起始治疗后早期(12 天)即可显现,并持续至长期随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, with or without diabetes, but additional data are needed about the effect of the drug on inpatient and outpatient events that reflect worsening heart failure. METHODS: We randomly assigned 3730 patients with class II to IV heart failure with an ejection fraction of ≤40% to double-blind treatment with placebo or empagliflozin (10 mg once daily), in addition to recommended treatments for heart failure, for a median of 16 months. We prospectively collected information on inpatient and outpatient events reflecting worsening heart failure and prespecified their analysis in individual and composite end points. RESULTS: Empagliflozin reduced the combined risk of death, hospitalization for heart failure or an emergent/urgent heart failure visit requiring intravenous treatment (415 versus 519 patients; empagliflozin versus placebo, respectively; hazard ratio [HR], 0.76; 95% CI, 0.67-0.87; P<0.0001). This benefit reached statistical significance at 12 days after randomization. Empagliflozin reduced the total number of heart failure hospitalizations that required intensive care (HR, 0.67; 95% CI, 0.50-0.90; P=0.008) and that required a vasopressor or positive inotropic drug or mechanical or surgical intervention (HR, 0.64; 95% CI, 0.47-0.87; P=0.005). As compared with placebo, fewer patients in the empagliflozin group reported intensification of diuretics (297 versus 414 [HR, 0.67; 95% CI, 0.56-0.78; P<0.0001]). Additionally, patients assigned to empagliflozin were 20% to 40% more likely to experience an improvement in New York Heart Association functional class and were 20% to 40% less likely to experience worsening of New York Heart Association functional class, with statistically significant effects that were apparent 28 days after randomization and maintained during long-term follow-up. The risk of any inpatient or outpatient worsening heart failure event in the placebo group was high (48.1 per 100 patient-years of follow-up), and it was reduced by empagliflozin (HR, 0.70; 95% CI, 0.63-0.78; P<0.0001). CONCLUSIONS: In patients with heart failure and a reduced ejection fraction, empagliflozin reduced the risk and total number of inpatient and outpatient worsening heart failure events, with benefits seen early after initiation of treatment and sustained for the duration of double-blind therapy. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03057977.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Packer M, Anker SD, Butler J, et al. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation. 2020. PMID: 33081531. doi:10.1161/CIRCULATIONAHA.120.051783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。